Quantification and Brain Targeting of Eugenol-Loaded Surface Modified Nanoparticles Through Intranasal Route in the Treatment of Cerebral Ischemia

Ahmad, Niyaz; Ahmad, Rizwan; Alam, Md. Aftab; Ahmad, Farhan Jalees

doi:10.1055/a-0596-7288

Cited by 47 publications

(31 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reason for this difference was that CB had a lower molecular weight and fewer reactive groups than BSA. However, the sizes of both nanoparticles were less than 200 nm, and the nanoparticles were thus suitable for nose‐to‐brain delivery . To further confirm the formation of CB‐Gd‐Cy5.5 and BSA‐Gd‐Cy5.5 nanoparticles, the particle morphologies were characterized using SEM, AFM, and TEM imaging as shown in Figure b,c,e,f; and Figure S1, Supporting Information, which indicated the presence of spherical aggregates and was consistent with the abovementioned data.…”

Section: Resultssupporting

confidence: 79%

Efficient Cholera Toxin B Subunit‐Based Nanoparticles with MRI Capability for Drug Delivery to the Brain Following Intranasal Administration

Chen

Fan

et al. 2018

Macromolecular Bioscience

View full text Add to dashboard Cite

Alzheimer's disease (AD) is an incurable neurodegenerative brain disorder that exhibits clear pathologic changes in the hippocampus. Traditional drug delivery systems are ineffective due to the existence of the blood–brain barrier (BBB). In this study, an efficient, stable, and easily constructed nanosystem (CB‐Gd‐Cy5.5) based on the cholera toxin B subunit (CB) is designed to improve the efficiency of drug delivery to the brain, especially the hippocampus. Through intranasal administration, CB‐Gd‐Cy5.5 is easily delivered to the brain without intervention by the BBB. The CB in CB‐Gd‐Cy5.5 is used for specifically combining with the monosialoganglioside GM1, which is widely found in the hippocampus. This nanosystem exhibits impressive performance in accumulating in the hippocampus. In addition, the good magnetic resonance imaging (MRI) capability of CB‐Gd‐Cy5.5 can satisfy the monitoring of AD in the different stages.

show abstract

Section: Resultssupporting

confidence: 79%

Efficient Cholera Toxin B Subunit‐Based Nanoparticles with MRI Capability for Drug Delivery to the Brain Following Intranasal Administration

Chen

Fan

et al. 2018

Macromolecular Bioscience

View full text Add to dashboard Cite

show abstract

“…A previous study showed that eugenol could protect against hepatic ischemia-reperfusion injury (Abd El Motteleb et al, 2014). Importantly, studies have suggested that eugenol has beneficial effects on cerebral ischemic injury (Won et al, 1998;Ahmad et al, 2018). In addition, a similar compound methyleugenol was demonstrated to alleviate cerebral ischemic injury via inhibiting oxidative stress, inflammation, and apoptosis (Choi et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

Eugenol Attenuates Cerebral Ischemia-Reperfusion Injury by Enhancing Autophagy via AMPK-mTOR-P70S6K Pathway

et al. 2020

View full text Add to dashboard Cite

Eugenol, as an active compound isolated from Acorus gramineus, has been shown to protect against cerebral ischemia-reperfusion (I/R) injury. Nonetheless, the detailed neuroprotective mechanisms of eugenol in cerebral I/R injury have not been elaborated. In the present study, cerebral I/R injury model was established by middle cerebral artery occlusion (MCAO) in rats. HT22 cells were subjected to oxygen-glucose deprivation/ reperfusion (OGD/R) to mimic cerebral I/R injury in vitro. The results showed that eugenol pre-treatment relieved cerebral I/R injury as evidenced by improving neurological deficits and reducing infarct volume. Autophagy was induced by MCAO, which was further promoted by eugenol administration. Moreover, rapamycin, an activator of autophagy, promoted eugenol-induced decreases in neurological score, infarct volume, brain water content, and apoptosis. However, pretreatment with 3-MA, an inhibitor of autophagy, led to the opposite results. Similarly, eugenol pretreatment increased the viability and restrained apoptosis of OGD/R-challenged HT22 cells. OGD/R-induced autophagy was strengthened by eugenol. Mechanically, eugenol promoted autophagy through regulating AMPK/mTOR/P70S6K signaling pathway in vivo and in vitro. In conclusion, pretreatment with eugenol attenuated cerebral I/R injury by inducing autophagy via AMPK/mTOR/ P70S6K signaling pathway.

show abstract

“…Finally, it was shown that higher cytotoxicity was achieved by the delivery of anti-miR-21 and pemetrexed through a lipid-polymer hybrid NPs. Ahmad et al investigated the beneficial effects of eugenol-encapsulated-CS-coated-PCL NPs for the treatment of cerebral ischemia [130]. It was shown that IN administration of these NPs increases their bioavailability in the rat brain and these NPs may lead to the treatment of cerebral ischemia.…”

Section: Poly (ε-Caprolactone) (Pcl)mentioning

confidence: 99%

Multifunctional Polymeric Nanoplatforms for Brain Diseases Diagnosis, Therapy and Theranostics

et al. 2020

View full text Add to dashboard Cite

The blood–brain barrier (BBB) acts as a barrier to prevent the central nervous system (CNS) from damage by substances that originate from the blood circulation. The BBB limits drug penetration into the brain and is one of the major clinical obstacles to the treatment of CNS diseases. Nanotechnology-based delivery systems have been tested for overcoming this barrier and releasing related drugs into the brain matrix. In this review, nanoparticles (NPs) from simple to developed delivery systems are discussed for the delivery of a drug to the brain. This review particularly focuses on polymeric nanomaterials that have been used for CNS treatment. Polymeric NPs such as polylactide (PLA), poly (D, L-lactide-co-glycolide) (PLGA), poly (ε-caprolactone) (PCL), poly (alkyl cyanoacrylate) (PACA), human serum albumin (HSA), gelatin, and chitosan are discussed in detail.

show abstract

Quantification and Brain Targeting of Eugenol-Loaded Surface Modified Nanoparticles Through Intranasal Route in the Treatment of Cerebral Ischemia

Abstract: Intranasal administration of developed CS-coated-EUG-loaded-PCL-NPs enhanced the drug bioavailability in rat brain and thus preparation of Eugenol-NPs may help treat cerebral ischemia effectively. The toxicity studies performed at the end revealed safe nature of optimized nanoformulation.

Cited by 47 publications

References 70 publications

Efficient Cholera Toxin B Subunit‐Based Nanoparticles with MRI Capability for Drug Delivery to the Brain Following Intranasal Administration

Efficient Cholera Toxin B Subunit‐Based Nanoparticles with MRI Capability for Drug Delivery to the Brain Following Intranasal Administration

Eugenol Attenuates Cerebral Ischemia-Reperfusion Injury by Enhancing Autophagy via AMPK-mTOR-P70S6K Pathway

Multifunctional Polymeric Nanoplatforms for Brain Diseases Diagnosis, Therapy and Theranostics

Contact Info

Product

Resources

About